Reasons for Discontinuation of Insulin Therapy—Results from the International Diabetes Management Practices Study (IDMPS)
Sign Up to like & getrecommendations! Published in 2018 at "Diabetes"
DOI: 10.2337/db18-1026-p
Abstract: Adherence to insulin therapy is often suboptimal. Understanding patients’ perspectives on drug adherence is essential for identification of barriers to therapy. The IDMPS is a global observational survey on the management of people with type… read more here.
Keywords: advisory panel; speaker9s bureau; self; panel self ... See more keywords
Initiating Basal Insulin Supported Oral Therapy (BOT) with Insulin Glargine 300 U/mL (Gla-300) Improves Glycemic Control in Patients (Pts) with Type 2 Diabetes (T2DM) without Increasing Hypoglycemia Risk
Sign Up to like & getrecommendations! Published in 2018 at "Diabetes"
DOI: 10.2337/db18-1027-p
Abstract: Toujeo-1, a prospective observational study, investigates the effects of initiating BOT with Gla-300 in insulin-naive pts with T2DM in Germany (n=1,680) and Switzerland, insufficiently controlled (A1c 7.5-10%) on oral antidiabetic drugs (OADs) in daily clinical… read more here.
Keywords: insulin; advisory panel; gmbh; self ... See more keywords
Impact of Background Antihyperglycemic Therapy on Insulin Glargine 300 U/mL (Gla-300) vs. Insulin Degludec 100 U/mL (IDeg-100) in Insulin-Naïve People with T2DM from the BRIGHT Randomized Study
Sign Up to like & getrecommendations! Published in 2018 at "Diabetes"
DOI: 10.2337/db18-1029-p
Abstract: BRIGHT (NCT02738151), the first head-to-head trial of Gla-300 and IDeg-100 in T2DM, is a multicenter, open-label, randomized, parallel-group, 24-week actively controlled study, conducted in insulin-naive participants uncontrolled on current antihyperglycemic drugs. Participants (mean baseline HbA… read more here.
Keywords: advisory panel; self; panel self; self sanofi ... See more keywords
Real-World Clinical Outcomes of Type 2 Diabetes (T2D) Patients Switching From Insulin Glargine 100 U/mL (Gla-100) or Insulin Detemir (IDet) to Insulin Glargine 300 U/mL (Gla-300) or Insulin Degludec (IDeg)—DELIVER D+ Subgroup Analyses
Sign Up to like & getrecommendations! Published in 2018 at "Diabetes"
DOI: 10.2337/db18-1056-p
Abstract: This retrospective, observational study compared clinical outcomes of adults with T2D switching from Gla-100/IDet to Gla-300 or IDeg. Electronic medical records (Predictive Health Intelligence Environment database) (3/1/15-1/31/17) were analyzed. Switchers with ≥1 A1C during 6—month… read more here.
Keywords: self; inc; self sanofi; research support ... See more keywords
Mortality Risk in Adults With and Without Type 2 Diabetes after 18 Years of Follow-up in Northern Spain—The Asturias Study
Sign Up to like & getrecommendations! Published in 2018 at "Diabetes"
DOI: 10.2337/db18-199-lb
Abstract: Objective: People who develop type 2 diabetes (T2D) have higher mortality risk. Regarding Asturias Study, after 18 years of follow-up, we have estimated all-cause, cardiovascular and cancer mortality-risks according to categories of impaired glucose metabolism.… read more here.
Keywords: asturias study; mortality risk; speaker9s bureau; mortality ... See more keywords
Similar or Lower Severe Hypoglycemia Rates with Insulin Glargine 300 U/mL (Gla-300) vs. Glargine 100 U/mL (Gla-100), Detemir (IDet), and Insulin Degludec (IDeg) in 112,626 People with Type 2 Diabetes Mellitus (T2DM)—Predictive Modeling Using Real-World Data—Lightning
Sign Up to like & getrecommendations! Published in 2018 at "Diabetes"
DOI: 10.2337/db18-2289-pub
Abstract: Real-world U.S. electronic health record (EHR) data, representative of the general population and real-life practice, were used to predict hypoglycemia rates in people with T2DM prescribed basal insulin (BI) analogs. Hypoglycemic events during BI treatment,… read more here.
Keywords: self; support self; self sanofi; research support ... See more keywords
Frequency of High Blood Pressure and Dyslipidemia in T1D and T2D—Results from the International Diabetes Management Practices Study (IDMPS)
Sign Up to like & getrecommendations! Published in 2018 at "Diabetes"
DOI: 10.2337/db18-621-p
Abstract: Appropriate disease management for people with diabetes requires control of not only blood glucose levels but also blood pressure and serum lipid profiles. The International Diabetes Management Practices Study (IDMPS) is a global observational survey… read more here.
Keywords: advisory panel; speaker9s bureau; self; panel self ... See more keywords
1105-P: Impact of Switching from Twice-Daily Basal Insulin (BI) to Once-Daily Insulin Glargine 300 U/mL (Gla-300) in Patients with Type 1 Diabetes (T1DM): Phase 4 Optimize Study
Sign Up to like & getrecommendations! Published in 2019 at "Diabetes"
DOI: 10.2337/db19-1105-p
Abstract: The 28-week, prospective, multicenter, open-label OPTIMIZE study, conducted in Belgium (presented at ADA 2018) and Canada, evaluated treatment optimization with once-daily (OD) Gla-300 in combination with a prandial insulin analog in adults with T1DM previously… read more here.
Keywords: self sanofi; sanofi; optimize study; insulin ... See more keywords
133-LB: High Hypoglycemia Risk Patients with T2D on First-Generation Basal Insulins (BI) in the U.S. Have a Lower Risk of Hypoglycemia after One Year following Switch to Insulin Glargine 300 U/mL (Gla-300) vs. First-Generation BIs (DELIVER - High Risk)
Sign Up to like & getrecommendations! Published in 2019 at "Diabetes"
DOI: 10.2337/db19-133-lb
Abstract: DELIVER - High Risk study compared long-term clinical outcomes for patients with T2D and high hypoglycemia risk on first-generation BIs who were switched to Gla-300 or other first-generation BIs (other switchers). Electronic medical record data… read more here.
Keywords: first generation; hypoglycemia; self sanofi; inc ... See more keywords
103-LB: Real-World Persistence, Adherence, Health Care Resource Utilization, and Costs in People with Type 2 Diabetes (T2D) Switching from Basal Insulin (BI) to Second-Generation BI (Insulin Glargine 300 U/mL [Gla-300]) vs. First-Generation BI (Insulin Glargine 1
Sign Up to like & getrecommendations! Published in 2021 at "Diabetes"
DOI: 10.2337/db21-103-lb
Abstract: This retrospective observational study using the Optum Clinformatics claims database included data from adults (≥18 y) with T2D who had received prior basal insulin (BI) (NPH, Gla-100, IDet) in the 6-month baseline period, and switched… read more here.
Keywords: insulin; sanofi; gla; generation ... See more keywords
745-P: Effectiveness and Safety of Insulin Glargine 300 U/mL (Gla-300) in Insulin-Naïve People with Type 2 Diabetes (T2DM): ATOS Study Subgroup Analysis by Baseline (BL) HbA1c
Sign Up to like & getrecommendations! Published in 2021 at "Diabetes"
DOI: 10.2337/db21-745-p
Abstract: ATOS was a 12-month prospective observational study in 18 countries outside US and Western Europe in insulin-naive adults with T2DM, uncontrolled (HbA1c >7-≤11%) on ≥1 oral antihyperglycemic drug. In this subgroup analysis participants were stratified… read more here.
Keywords: insulin; subgroup analysis; sanofi; self sanofi ... See more keywords